Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human leukocyte antigen class I histocompatibility antigen A-24 (HLA-A*24) is a cell surface MHC class I protein encoded by the HLA-A gene, highly polymorphic and found on most nucleated cells. It binds short peptide fragments derived from intracellular proteins and presents them to CD8+ cytotoxic T lymphocytes, enabling immune surveillance against infected or malignant cells. The HLA-A*24 variant is one of many alleles with unique peptide-binding preferences that influence susceptibility to infectious, autoimmune, and neoplastic diseases as well as transplant outcomes[2][3][4][5][7][8].
Presentation of intracellular peptide antigens (including viral, tumor, and self-peptides) to CD8+ T lymphocytes, triggering immune responses[2][3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human leukocyte antigen class I histocompatibility antigen A-24 (HLA-A*24).